Tuesday, December 11, 2018 10:55 AM
WEED's ''End-of-Year Scientific Research Conference'' brings successful results to it's 5-year Comprehensive Cannabis Integrated Molecular Breeding Platform
TUCSON, AZ / ACCESSWIRE / December 11, 2018 / WEED, Inc. (OTCQB: BUDZ) (the ''Company'') or (''WEED'') announced that its first of many cultivar DNA sequencing tests have been perfected and finalized. WEED's team of scientists is currently going thru the analytics evaluation and reports are forthcoming. ''During this time our team designed, tested, and refined standard operating procedures for efficient DNA isolation and sequencing of Cannabis genomes. Extensive bioinformatics analysis of repeatable and variable regions has been performed on newly-generated DNA sequencing data of 26 landrace cultivars and several publicly available genomes.'' stated CEO, Glenn E Martin.
Dr. George Golovko & Dr. Kamil Khanipov of Industrial Metagenomics stated goals for WEED, include, but are not limited to, ''this is the first phase of the Company's announced 5-year genomic research study, the results of this analysis will allow WEED Inc. to move forward towards a guided breeding program to further extend the development of a comprehensive genomic resource for effective breeding and identification of Cannabis plants.''
Dr. George commented further, ''The first part of the second phase of the program will include the development of a reference genome and transcriptome which will serve as a representative. The references will be used for genotyping to generate a range of proprietary data and suite of products accessible exclusively to WEED Inc.''
''Completion of these tasks will allow WEED, Inc. to create a Universal Genotyping Assay (UGA) for Cannabis cultivars to genetically identify and classify cultivars in a low-cost high throughput manner. The UGA will be a vital component in the decision-making process for robotic molecular breeding systems.'' added Dr Khanipov.
The final goal of the genomic studies is the development of a database for the Comprehensive Molecular Breeding Platform connecting cultivar's properties (e.g., THC, CBD, disease resistance, acceptable growth conditions) and their genetic signatures. To achieve these goals, WEED Inc is planning to design a genotyping assay to determine the cultivar's genetic profile and be able to perform comprehensive molecular-based breeding of thousands of cultivars in a quick and inexpensive way. The Company expects that this data, in concert with cultivar's chemical profiles, will allow it to computationally predict Quantitative Trait Loci (a region of the genome that correlates to plant's traits). A database of these genomic regions, QTLs, and associated chemical profiles comprehensive knowledge base will be the key to create ''designer'' cultivars.
WEEDs ''End-of-Year conference''. will include, WEED's group of highly skilled PHDs flying in from around the country to Tucson December 19th thru 22nd. Also, via satelite, WEEDS Phd teams from WEED Israel Cannabis Ltd., & WEED Australia Ltd will attend.
About WEED, Inc.
WEED, Inc. (OTCQB: BUDZ) is currently a USA-based fully reporting public company. WEED Inc. is a multi-national, multi-faceted, vertically-integrated world class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to achieve and promote our global brand. WEED is dedicated to its global goals and outreach across the full spectrum of the Cannabis industry to find treatments, therapies and medical cures utilizing the Cannabaceae plant family. WEED does not grow, harvest, produce, or sell any substance in violation of US Federal law under The Federal Controlled Substances Act, and meets all standards of international law for WEED, Inc. and its subsidiaries in foreign locations. For additional information about WEED, Inc., please visit www.WEEDIncUSA.com.
About Sangre AT, LLC
Sangre AT, LLC (dba "Sangre AgroTech") is a wholly-owned subsidiary of WEED, Inc., and is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. For additional information about Sangre AgroTech, please visit www.sangreagrotech.com.
This release contains forward-looking statements. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business, including that we have a limited operating history and very limited funds, are dependent upon key personnel whose loss may adversely impact our business, some of our potential business activities, while believed to be compliant with applicable state law, may be illegal under federal law because they violate the Federal Controlled Substances Act, and we may be subject to the risks related to the cost, delays and uncertainties associated with potential future scientific research, product development, clinical trials and the regulatory approval process. We may not be able to enter into binding agreements related to the subject matter of this press release on terms favorable to us or at all. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
For more information, contact:
Glenn E. Martin at (520) 818-8582
SOURCE: WEED, Inc.